Astellas Pharma Inc.announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-t...
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Company has entered ...
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced that Leqembi is now available at a private clinic in Sweden and that the first patie...
NanoImaging Services, a cryo-EM CRO, and Proteos, a protein production research partner, have announced the launch of TrueCourse Biosciences, an in...
Andelyn Biosciences (“Andelyn”), a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (&ldqu...
IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, announced...
Silo Pharma (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug del...
EB Development, a company owned directly or indirectly by funds managed by IK Partners and former reference shareholders of Eurobio Scientific (FR0013240...
Roche announced that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/R...
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announced that it has...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), has established a formal collaboration with X-Chem, a data...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval...
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the ri...
© 2026 Biopharma Boardroom. All Rights Reserved.
